# LMOD2

## Overview
Leiomodin 2 (LMOD2) is a gene that encodes the protein leiomodin 2, which plays a critical role in the regulation of actin filament dynamics, particularly within muscle cells. Leiomodin 2 is categorized as an actin-binding protein and is essential for the proper assembly and maintenance of muscle thin filaments, contributing to muscle contraction and sarcomere organization. The protein is characterized by its ability to bind to actin and tropomyosin, facilitating actin nucleation and elongation at the pointed ends of thin filaments. This function is crucial for maintaining the structural integrity and contractile function of cardiac and skeletal muscles. Mutations in the LMOD2 gene have been linked to severe cardiac conditions, such as dilated cardiomyopathy, underscoring its importance in cardiac health (Sono2023WholeExome; Iwanski2024Leiomodin; Szatmári2017Cardiac).

## Structure
Leiomodin 2 (LMOD2) is a protein characterized by several distinct structural domains that contribute to its function in actin filament regulation. The protein includes a tropomyosin-binding domain near the N-terminus, which facilitates its interaction with tropomyosin, forming a complex that regulates actin polymerization at the pointed end of thin filaments (Sono2023WholeExome; Tolkatchev2020Leiomodin). LMOD2 also contains three actin-binding sites: A1, located after the tropomyosin-binding site; A2, which consists of a leucine-rich repeat (LRR) domain; and A3, which is a Wiskott-Aldrich-Syndrome protein homology 2 (WH2) domain near the C-terminus (Iwanski2024Leiomodin).

The secondary structure of LMOD2 includes α-helices and β-loops, with the N-terminal region being dynamic and the C-terminal region forming two α-helices (Tolkatchev2020Leiomodin). The protein's tertiary structure is stabilized by hydrophobic interactions, particularly involving leucine residues that engage with tropomyosin (Tolkatchev2020Leiomodin). The quaternary structure involves the formation of a 4-helix bundle when LMOD2 binds to tropomyosin, which is crucial for its role as a 'leaky cap' at the pointed end of actin filaments (Tolkatchev2020Leiomodin). This structural configuration allows LMOD2 to regulate filament length by permitting limited actin polymerization (Tolkatchev2020Leiomodin).

## Function
Leiomodin 2 (LMOD2) is a crucial protein involved in the regulation of actin filament dynamics within muscle cells, particularly in cardiac and skeletal muscle tissues. It plays a significant role in the assembly and maintenance of muscle thin filaments by promoting actin nucleation and elongation, which are essential for proper muscle contraction and sarcomere organization (Sono2023WholeExome; Szatmári2017Cardiac). LMOD2 binds to the pointed ends of actin filaments, facilitating their elongation to reach mature lengths necessary for effective contractile force generation in cardiac muscle (Sono2023WholeExome).

In healthy human cells, LMOD2 acts as a potent nucleator of actin filaments, contributing to the proper organization and function of myofibrils. It possesses multiple actin-binding sites, including a WH2 domain, which is particularly important for its elongation function (Iwanski2024Leiomodin). LMOD2 also interacts with tropomyosin, a muscle actin-binding protein, which modulates its activity by enhancing capping activity and influencing actin polymerization rates (Szatmári2017Cardiac).

The protein's activity is crucial for maintaining the structural integrity and function of the cardiac sarcomere, the fundamental contractile unit of cardiac muscle, thereby ensuring normal cardiac contractility and preventing cardiac diseases associated with thin filament abnormalities (Yuen2022Neonatallethal).

## Clinical Significance
Mutations in the LMOD2 gene are associated with severe forms of dilated cardiomyopathy (DCM), particularly in neonates and infants. These mutations often result in truncated proteins due to nonsense or frameshift mutations, leading to a lack of functional LMOD2 protein. This is primarily due to nonsense-mediated mRNA decay, a cellular mechanism that degrades mRNAs with premature termination codons, preventing the expression of full-length proteins (Sono2023WholeExome; Pappas2024Human). 

The absence or dysfunction of LMOD2 disrupts the regulation of actin-thin filaments in cardiac muscle cells, leading to structural abnormalities such as shortened thin filaments and disorganized myofibrils. These changes impair cardiac contractility and can result in heart failure (Sono2023WholeExome; Iwanski2024Leiomodin). Specific mutations, such as the p.W398* variant, have been linked to severe neonatal DCM, characterized by early-onset heart failure and, in some cases, neonatal death (Sono2023WholeExome; Yuen2022Neonatallethal).

Research has explored potential therapeutic strategies, such as using steric-blocking oligonucleotides to prevent nonsense-mediated decay, aiming to restore mutant protein expression and improve cardiac function (Pappas2024Human). However, these approaches are still under investigation and are not yet clinically available.

## Interactions
Leiomodin 2 (LMOD2) interacts with several proteins, primarily involving actin and tropomyosin, to regulate actin filament dynamics. LMOD2 binds to actin filaments through its actin-binding sites (ABS1 and ABS2), with ABS2 playing a crucial role in actin nucleation by recruiting actin subunits (Boczkowska2015How). Unlike tropomodulin (Tmod), LMOD2 does not compete for binding at the pointed end of actin filaments, allowing it to nucleate actin polymerization effectively (Boczkowska2015How).

LMOD2 also interacts with tropomyosin, forming a complex that influences filament elongation. The interaction is mediated by specific residues in LMOD2, such as those in the N-terminal region, which are crucial for binding to tropomyosin peptides (Tolkatchev2020Leiomodin). The binding interface between LMOD2 and α-tropomyosin involves residues Arg7-Glu41 of LMOD2 and the N-terminal residues of tropomyosin (Colpan2016Localization). Mutations in LMOD2, such as L25G, can reduce its affinity for tropomyosin, affecting its ability to elongate thin filaments and displace Tmod1 from the pointed ends (Tolkatchev2020Leiomodin).

These interactions are essential for LMOD2's function in actin dynamics, particularly in muscle cells, where it regulates thin filament length and stability (Tolkatchev2021The).


## References


[1. (Boczkowska2015How) Malgorzata Boczkowska, Grzegorz Rebowski, Elena Kremneva, Pekka Lappalainen, and Roberto Dominguez. How leiomodin and tropomodulin use a common fold for different actin assembly functions. Nature Communications, September 2015. URL: http://dx.doi.org/10.1038/ncomms9314, doi:10.1038/ncomms9314. This article has 39 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms9314)

[2. (Sono2023WholeExome) Reiri Sono, Tania M. Larrinaga, Alden Huang, Frank Makhlouf, Xuedong Kang, Jonathan Su, Ryan Lau, Valerie A. Arboleda, Reshma Biniwale, Gregory A. Fishbein, Negar Khanlou, Ming-Sing Si, Gary M. Satou, Nancy Halnon, Glen S. Van Arsdell, Carol C. Gregorio, Stanly Nelson, and Marlin Touma. Whole-exome sequencing identifies homozygote nonsense variants in lmod2 gene causing infantile dilated cardiomyopathy. Cells, 12(11):1455, May 2023. URL: http://dx.doi.org/10.3390/cells12111455, doi:10.3390/cells12111455. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells12111455)

[3. (Iwanski2024Leiomodin) Jessika B. Iwanski, Christopher T. Pappas, Rachel M. Mayfield, Gerrie P. Farman, Rebecca Ahrens-Nicklas, Jared M. Churko, and Carol C. Gregorio. Leiomodin 2 neonatal dilated cardiomyopathy mutation results in altered actin gene signatures and cardiomyocyte dysfunction. npj Regenerative Medicine, September 2024. URL: http://dx.doi.org/10.1038/s41536-024-00366-y, doi:10.1038/s41536-024-00366-y. This article has 0 citations.](https://doi.org/10.1038/s41536-024-00366-y)

[4. (Yuen2022Neonatallethal) Michaela Yuen, Lisa Worgan, Jessika Iwanski, Christopher T. Pappas, Himanshu Joshi, Jared M. Churko, Susan Arbuckle, Edwin P. Kirk, Ying Zhu, Tony Roscioli, Carol C. Gregorio, and Sandra T. Cooper. Neonatal-lethal dilated cardiomyopathy due to a homozygous lmod2 donor splice-site variant. European Journal of Human Genetics, 30(4):450–457, January 2022. URL: http://dx.doi.org/10.1038/s41431-022-01043-8, doi:10.1038/s41431-022-01043-8. This article has 13 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41431-022-01043-8)

[5. (Szatmári2017Cardiac) Dávid Szatmári, Beáta Bugyi, Zoltán Ujfalusi, László Grama, Réka Dudás, and Miklós Nyitrai. Cardiac leiomodin2 binds to the sides of actin filaments and regulates the atpase activity of myosin. PLOS ONE, 12(10):e0186288, October 2017. URL: http://dx.doi.org/10.1371/journal.pone.0186288, doi:10.1371/journal.pone.0186288. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0186288)

[6. (Colpan2016Localization) Mert Colpan, Dmitri Tolkatchev, Samantha Grover, Gregory L. Helms, John R. Cort, Natalia Moroz, and Alla S. Kostyukova. Localization of the binding interface between leiomodin-2 and α-tropomyosin. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1864(5):523–530, May 2016. URL: http://dx.doi.org/10.1016/j.bbapap.2016.02.009, doi:10.1016/j.bbapap.2016.02.009. This article has 26 citations.](https://doi.org/10.1016/j.bbapap.2016.02.009)

[7. (Tolkatchev2021The) Dmitri Tolkatchev, Carol C. Gregorio, and Alla S. Kostyukova. The role of leiomodin in actin dynamics: a new road or a secret gate. The FEBS Journal, 289(20):6119–6131, July 2021. URL: http://dx.doi.org/10.1111/febs.16128, doi:10.1111/febs.16128. This article has 9 citations.](https://doi.org/10.1111/febs.16128)

[8. (Tolkatchev2020Leiomodin) Dmitri Tolkatchev, Garry E. Smith, Lauren E. Schultz, Mert Colpan, Gregory L. Helms, John R. Cort, Carol C. Gregorio, and Alla S. Kostyukova. Leiomodin creates a leaky cap at the pointed end of actin-thin filaments. PLOS Biology, 18(9):e3000848, September 2020. URL: http://dx.doi.org/10.1371/journal.pbio.3000848, doi:10.1371/journal.pbio.3000848. This article has 17 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1371/journal.pbio.3000848)

[9. (Pappas2024Human) Christopher T. Pappas, Rachel M. Mayfield, Ava E. Dickerson, Lei Mi-Mi, and Carol C. Gregorio. Human disease-causing mutations result in loss of leiomodin 2 through nonsense-mediated mrna decay. PLOS Genetics, 20(5):e1011279, May 2024. URL: http://dx.doi.org/10.1371/journal.pgen.1011279, doi:10.1371/journal.pgen.1011279. This article has 2 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1011279)